Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

OncoMed Pharmaceuticals, Inc. Therapeutic Pipeline Market Review, H2 2016

Tuesday, October 11, 2016 22:16
% of readers think this story is Fact. Add your two cents.

(Before It's News)



 ‘OncoMed Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the OncoMed Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by OncoMed Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Make an enquiry before buying this Report @         


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @


- The report provides a snapshot of the pipeline therapeutic landscape of OncoMed Pharmaceuticals, Inc.
- The report provides overview of OncoMed Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses OncoMed Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features OncoMed Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate OncoMed Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for OncoMed Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding OncoMed Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Buy this report @

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
OncoMed Pharmaceuticals, Inc. Snapshot 6
OncoMed Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
OncoMed Pharmaceuticals, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
OncoMed Pharmaceuticals, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
OncoMed Pharmaceuticals, Inc. – Pipeline Products Glance 14
OncoMed Pharmaceuticals, Inc. – Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
OncoMed Pharmaceuticals, Inc. – Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
OncoMed Pharmaceuticals, Inc. – Drug Profiles 17
demcizumab 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
tarextumab 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
brontictuzumab 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ipafricept 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
OMP-131R10 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
OMP-305B83 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
vantictumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IO-2 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IO-3 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody to Agonize GITR for Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody to Inhibit Hippo Pathway for Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OncoMed Pharmaceuticals, Inc. – Pipeline Analysis 37
OncoMed Pharmaceuticals, Inc. – Pipeline Products by Target 37
OncoMed Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 38
OncoMed Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 39
OncoMed Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action 40
OncoMed Pharmaceuticals, Inc. – Recent Pipeline Updates 41
OncoMed Pharmaceuticals, Inc. – Dormant Projects 61
OncoMed Pharmaceuticals, Inc. – Discontinued Pipeline Products 62
Discontinued Pipeline Product Profiles 62
brontictuzumab 62
tarextumab 62
OncoMed Pharmaceuticals, Inc. – Locations And Subsidiaries 63
Head Office 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

Complete report details @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.